The approval of AIM Vaccine's mRNA RSV vaccine for clinical trials in the U.S. is seen by analysts as further validation of the company's "Innovation + Expansion" capabilities, potentially providing ...
Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback